

-SUPPORTING INFORMATION-

Iron-catalyzed synthesis of oxindoles: application to the preparation of pyrroloindolines

Valquírio G. Correia,[‡] Juliana C. Abreu,[‡] Caio A. E. Barata and Leandro H. Andrade*

Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, SP 05508-900, São Paulo (Brazil).


Table of Contents

A. General information.....	S2
B. General procedure for the preparation of <i>N</i>-Arylacrylamides.....	S2
C. General procedure for the Methylation of <i>N</i>-Arylacrylamides.....	S5
D. General procedure for the preparation of <i>N</i>-butyl and <i>N</i>-phenyl formamides	S7
E. Typical procedure for carbamoylation with formamide.....	S7
F. Typical procedure for carbamoylation with <i>N</i>-alkyl or <i>N</i>-aryl-formamides.....	S10
G. Procedure for direct conversion of 6a to the corresponding methyl ester.....	S13
H. ¹H and ¹³C NMR Spectra for the compounds prepared.....	S14


A. General Information

The reagents were purchased from Sigma-Aldrich. Solvents were purified by standard procedures. Reactions were monitored using GCM-QP2010SE (Shimadzu) with low-resolution electron impact (EI, 70 eV) equipped with a RTX®-5MS capillary column. GC/MS conditions: injector 260°C; detector: 110°C; pressure: 100 kPa. Column temperature: 80°C, 1°C/min up to 280°C. Thin-layer chromatography (TLC) was conducted with Merck silica gel 60 F254 precoated plates and visualized with UV and vanillin stain. Flash column chromatography was performed on silica gel (200–300 mesh). ¹H NMR spectra were recorded on a Varian Inova-300 (300 MHz) spectrometer and are reported in ppm using TMS as an internal standard (CDCl₃ at δ 7.26 ppm). The following abbreviations were used to describe peak splitting patterns when appropriate: br s = broad singlet, s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. Coupling constant, *J*, was reported in hertz (Hz). Proton-decoupled ¹³C NMR spectra were recorded on a Varian-300 (75 MHz) spectrometer and are reported in ppm using TMS as an internal standard (CDCl₃ at δ 77.0). High-resolution mass spectra were recorded using MicroToF Bruker Daltonics, ESI-TOF techniques.


B. General procedure for the preparation of *N*-Arylacrylamides:¹




To a 250 mL round bottom flask charged with magnetic stirrer, aniline (20 mmol), pyridine (2.4 mL, 30 mmol) was added 80 mL anhydrous dichloromethane, under N₂ atmosphere. The resulting mixture was cooled to 0 °C, followed by the drop wise addition of methacryloyl chloride (2.34 mL, 24 mmol) and stirring 15 minutes. The mixture was brought to room temperature and stirred for 16 h. The reaction was quenched with 40 mL H₂O. The organic phase was washed with H₂O (40 mL), saturated NaHCO₃ (2 × 40 mL) and saturated NaCl (40 mL). The combined aqueous phase was extracted with dichloromethane (3 × 40 mL). The combined organic phase was dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel using ethyl acetate/hexane as eluent (15 to 30%, AcOEt). The product was characterized by ¹H NMR spectroscopy and mass spectrometry.




N-phenyl-methacrylamide (**a** or **1k**): ¹H NMR (CDCl₃, 300Hz) δ 7.55 (d, 2H, *J*=6.0 Hz), 7.33 (t, 2H, *J*=9.0 Hz), 7.12 (t, 1H, *J*=9.0 Hz), 5.78 (s, 1H), 5.45 (s, 1H, *J*=3.0 Hz), 2.06 (s, 3H) ppm.




N-(4-fluorophenyl)-methacrylamide (**b**): ¹H NMR (CDCl₃, 300Hz) δ 7.04 (d, 2H, *J*=9.0Hz), 6.84 (d, 2H, *J*=9.0Hz), 4.99 (s, 1H), 4.96 (s, 1H), 3.78 (s, 3H), 3.28 (s, 3H), 1.71 (s, 3H) ppm.




***N*-(4-Methylphenyl)-methacrylamide (c):** ^1H NMR (CDCl_3 , 300 MHz) δ 7.44 (d, 2H, $J=9$ Hz), 7.12 (d, 2H, $J=9$ Hz), 5.78 (s, 1H), 5.44 (s, 1H), 2.32 (s, 3H), 2.06 (s, 3H) ppm.




***N*-(4-methoxyphenyl)-methacrylamide (d):** ^1H NMR (CDCl_3 , 300Hz) δ 7.46 (d, 3H, $J=9.0$ Hz), 6.87 (d, 2H, $J=9.0$ Hz), 5.77 (s, 1H), 5.42 (s, 1H), 3.79 (s, 3H), 2.05 (s, 3H) ppm.




***N*-(4-chlorophenyl)-methacrylamide (e):** ^1H NMR (CDCl_3 , 300Hz) δ 7.76 (s, 1H), 7.52 (d, 2H, $J=9.0\text{Hz}$), 7.28 (d, 2H, $J=9.0\text{Hz}$), 5.78 (s, 1H), 5.45 (s, 1H), 2.03 (s, 3H) ppm.




***N*-(4-bromophenyl)-methacrylamide (f):** ^1H NMR (CDCl_3 , 300 Hz) δ 7.46 (d, 2H, $J=9.0\text{Hz}$), 7.41 (d, 2H, $J=9.0$ Hz), 5.77 (s, 1H), 5.44 (s, 1H), 2.02 (s, 3H) ppm.




***N*-([1,1'-biphenyl]-2-yl)-methacrylamide (g):** ^1H NMR (CDCl_3 , 300 MHz) δ 8.43 (d, 1H, $J=9\text{Hz}$), 7.64 (s, 1H) 7.54-7.37 (m, 6H), 7.29-7.16 (m, 2H), 5.54 (s, 1H), 5.31 (s, 1H), 1.85 (s, 3H) ppm.



***N*-(3-chlorophenyl)-methacrylamide (h):** ^1H NMR (CDCl_3 , 300 MHz) δ 7.70-7.68 (m, 1H), 7.50 (s, 1H), 7.42-7.39 (m, 1H), 7.28-7.23 (m, 1H), 7.12-7.08 (m, 1H), 5.79 (s, 1H), 5.49 (s, 1H), 2.06 (s, 3H) ppm.




***N*-(2-chlorophenyl)-methacrylamide (i):** ^1H NMR (300 MHz, CDCl_3) δ 8.47 (dd, 1H, $J=7.5$ Hz, $J=3$ Hz), 8.13 (s, 1H), 7.40-7.27 (m, 2H), 7.08-7.06 (m, 1H), 5.91 (s, 1H), 5.53 (s, 1H), 2.11 (s, 3H) ppm.




***N,N*-diphenylmethacrylamide (11):** ^1H NMR (300 MHz, CDCl_3) δ 7.36-7.31 (m, 4H), 7.26-7.15 (m, 6H), 5.23 (s, 1H), 5.17 (s, 1H), 1.84 (s, 3H) ppm.²

B.1 Procedure for the preparation of *N*-methyl-*N*-phenylcinnamamide:³




To a stirring solution of cinnamic acid (5 mmol) in dry CH₂Cl₂ (10 mL), the *N*-methylaniline (5 mmol) and 4-Dimethylaminopyridine (DMAP) (0.125 mmol) were added. The mixture was cooled to 0°C and *N,N'*-dicyclohexylcarbodiimide (DCC) (5 mmol) was added, then the mixture was maintained at 0°C. After 10 min, the reaction was allowed to reach room temperature and stirred for 18h. Subsequently, CH₂Cl₂ (10 mL) was added and the mixture was filtrated. Afterwards, the filtrate was washed with a 10% aqueous solution of HCl (2 × 10 mL) and with a saturated solution of Na₂CO₃ (2 × 10 mL). The combined organic extracts were dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel using ethyl acetate/hexane as eluent (10%, AcOEt).




***N*-methyl-*N*-phenylcinnamamide (1m):** ¹H NMR (300 MHz, CDCl₃) δ 7.68 (d, 1H, *J* = 18 Hz), 7.47-7.23 (m, 10H), 6.37 (d, 1H, *J* = 18 Hz), 3.42 (s, 3 H) ppm.


C. General procedure for the Methylation of *N*-Arylacrylamides:⁴




To a 250 mL round bottom flask charged with magnetic stirrer, a solution of *N*-acrylamide (20 mmol) in 32 mL THF was added to a suspension of NaH (1.2 g, 30 mmol) in 32 mL THF, under N₂. The mixture was stirred at 0 °C for 40 min. Subsequently, CH₃I (2.75 mL, 50 mmol) or BnBr (5.94 mL, 50 mmol) was added dropwise, and then mixture was brought to room temperature and stirred for 3 h. The reaction was quenched with H₂O (40 mL) and the aqueous phase was extracted with ethyl acetate (3 x 40 mL). The organic phase was washed with saturated NaCl (40 mL), dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel using ethyl acetate/hexane as eluent (15 to 30%, AcOEt). The product was characterized by ¹H, ¹³C NMR spectroscopy and mass spectrometry.




***N*-methyl-*N*-phenylmethacrylamide (1a):** ¹H NMR (CDCl₃, 300Hz) δ 7.32-7.36 (m, 2H), 7.23-7.28 (m, 1H), 7.12-7.15 (m, 2H), 5.03 (s, 1H), 4.99 (s, 1H), 3.35 (s, 3H), 1.71-1.77 (m, 3H); ¹³C NMR (CDCl₃, 75Hz) δ 172.0, 144.6, 140.7, 129.2, 126.9, 126.5 (2C), 119.3, 37.6, 20.3 ppm.⁵




***N*-(4-fluorophenyl)-*N*-methylmethacrylamide (1b):** ¹H NMR (CDCl₃, 300Hz) δ 7.06-7.11 (m, 2H), 6.96-7.04 (m, 2H), 5.02 (s, 1H), 4.95 (s, 1H), 3.29 (s, 3H), 1.73 (s, 3H); ¹³C NMR (CDCl₃, 75Hz) δ 171.9, 161.2 (d, *J*=247,5Hz), 140.5, 128.2 (d, *J*=7,5Hz), 119.3, 116.1 (d, *J*=22,5Hz), 37.8, 20.3 ppm.⁶




***N*-methyl-*N*-(4-tolyl)methacrylamide (1c):** ¹H NMR (300 MHz, CDCl₃) δ 7.14 (d, 2H, *J* = 9), 7.01 (d, 2H, *J* = 9), 5.02 (s, 1H), 4.99 (s, 1H), 3.32 (s, 3H), 2.35 (s, 3H), 1.76 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 172.04, 141.98, 140.78, 136.78, 129.80, 126.30, 119.09, 37.68, 20.98, 20.33 ppm.⁷




***N*-(4-methoxyphenyl)-*N*-methylmethacrylamide (1d):** ¹H NMR (CDCl₃, 300Hz) δ 7.03 (d, 2H, *J*=9.0Hz), 6.83 (d, 2H, *J*=9.0Hz), 4.99 (s, 1H), 4.96 (s, 1H), 3.78 (s, 3H), 3.28 (s, 3H), 1.71 (s, 3H); ¹³C NMR (CDCl₃, 75Hz) δ 20.3, 37.7, 55.3, 114.2 (2C), 118.8, 127.6 (2C), 137.3, 140.8, 158.2, 172.0 ppm.⁸




***N*-(4-chlorophenyl)-*N*-methylmethacrylamide (1e):** ^1H NMR (CDCl_3 , 300Hz) δ 7.30 (d, 2H, $J=6.0\text{Hz}$), 7.07 (d, 2H, $J=9.0\text{Hz}$), 5.06 (s, 1H), 4.97(s, 1H), 3.31 (s, 3H), 1.77 (s, 3H); ^{13}C NMR (CDCl_3 , 75Hz) δ 20.4, 37.8, 119.8, 127.9, 129.6, 132.7, 140.6, 143.3, 172.0 ppm.³




***N*-(4-bromophenyl)-*N*-methylmethacrylamide (1f):** ^1H NMR (CDCl_3 , 300Hz) δ 7.46 (d, 2H, $J=9.0\text{Hz}$), 7.01 (d, 2H, $J=9.0\text{Hz}$), 5.07 (s, 1H), 4.97(s, 1H), 3.31 (s, 3H), 1.77 (s, 3H); ^{13}C NMR (CDCl_3 , 75Hz) δ 20.3, 37.6, 119.7, 120.4, 128.0 (2C), 132.4 (2C), 140.3, 143.7, 171.7 ppm.³




***N*-([1,1'-biphenyl]-2-yl)-*N*-methylmethacrylamide (1g):** ^1H NMR (300 MHz, CDCl_3) δ 7.41-7.26 (m, 9H), 4.93 (s, 1H), 4.67 (s, 1H), 3.28 (s, 3H), 1.31 (s, 3H) ppm. ^{13}C NMR (75 MHz, CDCl_3) δ 142.28, 139.87, 138.76, 138.72, 131.27, 128.85, 128.73, 128.36, 128.02, 127.60, 127.50, 119.61, 38.43, 19.66 ppm.⁹



***N*-(3-chlorophenyl)-*N*-methylmethacrylamide (1h):** ^1H NMR (300 MHz, CDCl_3) δ 7.32-7.22 (m, 2H), 7.18-7.16 (m, 1H), 7.07-7.03 (m, 1H), 5.09 (s, 1H), 5.00 (s, 1H), 3.34 (s, 3H), 1.80 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 171.70, 145.75, 140.24, 134.56, 130.14, 126.99, 126.57, 124.64, 119.71, 37.56, 20.19 ppm.³



***N*-(2-chlorophenyl)-*N*-methylmethacrylamide (1i):** ^1H NMR (300 MHz, CDCl_3) δ 7.46-7.43 (m, 1H), 7.28-7.19 (m, 3H), 4.98 (s, 2H), 3.26 (s, 3H), 1.82 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 172.05, 140.13, 132.44, 130.52, 129.72, 128.94 (2C), 127.79, 118.48, 36.26, 20.10 ppm. IR (ATR), ν max: 2928, 1657, 1628, 1482, 1363, 1130, 1065, 765, 734 cm^{-1} . MS-EI: m/z (%) 174 (100), 77 (15), 69 (76), 41 (74). HRMS (ESI-TOF) m/z , calculated for $\text{C}_{11}\text{H}_{12}\text{ClNO} + \text{H}^+$ = 210.0686. Found: 210.0670.




***N*-benzyl-*N*-phenylmethacrylamide (1j):** ^1H NMR (CDCl_3 , 300Hz) δ 7.26-7.19 (m, 8H), 6.98 (d, 2H, $J=6.0\text{Hz}$), 5.04 (d, 2H, $J=6.0\text{Hz}$), 4.98 (s, 2H), 1.79 (s, 3H); ^{13}C NMR (CDCl_3 , 75Hz) δ 20.4, 53.2, 119.4, 127.1, 127.3, 127.4, 128.4, 129.1, 137.5, 140.7, 143.2, 171.8.³


D. General procedure for the preparation of *N*-butyl and *N*-phenyl formamides

The *N*-phenylformamide was synthesized according to a procedure described in the literature¹⁰ and *N*-butylformamide according to a procedure recently described by our research group.¹¹


E. Typical procedure for carbamoylation with formamide:¹²




To a stirring solution of *N*-arylacrylamide (1.00 mmol) and $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (2.8 mg, 0.01 mmol) in 5.0 mL of formamide was added sulfuric acid (56.0 μL , 1.00 mmol) followed by hydrogen peroxide (213.5 μL , 2.00 mmol). The mixture was heated to 65 °C and stirred for 4 h. Then sodium bicarbonate (330 mg, 3.9 mmol) was added and excess of formamide was removed under reduced pressure distillation. The crude mixture was purified by flash column chromatography on silica gel using methanol/dichloromethane as eluent (10 to 20%, methanol). The product was characterized by NMR spectroscopy, mass spectrometry and high resolution mass spectrometry.




2-(1,3-dimethyl-2-oxoindolin-3-yl)acetamide (2): (starting material: 2.0 mmol; 0.401 g. Yield, 92%. yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.29-7.26 (m, 2H), 7.11-7.06 (m, 1H), 6.86 (d, 1H, $J=9.0$ Hz), 6.42 (br s, 1H), 5.38 (br s, 1H), 3.24 (s, 3H), 2.82 (d, 1H, $J=15.0$ Hz), 2.68 (d, 1H, $J=15.0$ Hz), 1.44 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.5, 171.3, 142.8, 133.2, 128.2, 122.9, 122.7, 108.4, 46.0, 43.4, 26.4, 23.5 ppm; MS-EI: m/z (%) 218 (M^+ , 40), 160 (100).¹³




2-(5-fluor-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (6): (starting material: 2.0 mmol; 0.418 g. Yield, 90%. light brown solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.05-6.98 (m, 2H), 6.80-6.78 (m, 1H), 6.17 (br s, 1H), 5.25 (br s, 1H), 3.23 (s, 3H), 2.83 (d, 1H, $J=15.0$ Hz), 2.69 (d, 1H, $J=15.0$ Hz), 1.43 (s, 3H); ^{13}C NMR (CD_3OD , 75 MHz) δ 181.1, 172.6, 159.4 (d, C-F, $J=238$ Hz), 139.5, 135.2 (d, C-F, $J=8$ Hz), 113.6 (d, C-F, $J=24$ Hz), 110.1 (d, C-F, $J=25$ Hz), 108.9 (d, C-F, $J=8.25$ Hz), 46.2, 41.7, 25.4, 23.2 ppm; MS-EI: m/z (%) 236 (M^+ , 54), 178 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{12}\text{H}_{14}\text{FN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 237.1039, found: 237.1027.




2-(1,3,5-trimethyl-2-oxoindolin-3-yl)acetamide (7): (starting material: 2.0 mmol; 0.413 g. Yield, 89%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.09-7.07 (m, 2H), 6.75 (d, 1H, $J=6.0$ Hz), 6.54 (br s, 1H), 5.35 (br s, 1H), 3.22 (s, 3H), 2.80 (d, 1H, $J=15.0$ Hz), 2.66 (d, 1H, $J=15.0$ Hz), 2.34 (s, 3H), 1.44 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.5, 171.5, 140.3, 133.3, 132.5, 128.5, 123.6, 108.1, 46.0, 43.4, 26.5, 23.5, 21.2 ppm; MS-EI: m/z (%) 232 (M^+ , 38), 174 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 233.1290, found: 233.1291.




2-(5-methoxy-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (8): (starting material: 1.0 mmol; 0.226 g. Yield, 91%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 6.90 (d, 2H, $J=3.0$ Hz), 6.82-6.75 (m, 2H), 6.58 (br s, 1H), 5.31 (br s, 1H), 3.79 (s, 3H), 3.22 (s, 3H), 2.80 (d, 1H, $J=15.0$ Hz), 2.67 (d, 1H, $J=15.0$ Hz), 1.45 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.2, 171.3, 156.3, 136.1, 134.7, 112.4, 110.3, 108.7, 55.8, 46.3, 43.4, 26.5, 23.4 ppm; MS-EI: m/z (%) 248 (M^+ , 82), 190 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_3$ [$\text{M}+\text{H}$] $^+$ 249.1239, found: 249.1232 14




2-(5-chloro-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (9): (starting material: 5.0 mmol; 1.102 g. Yield, 87%. light brown solid) ^1H NMR (CD_3OD , 300 MHz) δ 7.31-7.25 (m, 2H), 6.94 (d, 1H, $J=6.0$ Hz), 3.30 (s, 2H), 3.21 (s, 3H), 2.86 (s, 2H), 1.31 (s, 3H); ^{13}C NMR (CD_3OD , 75 MHz) δ 180.96, 172.56, 142.26, 135.31, 127.51, 127.43, 122.46, 109.34, 45.99, 41.69, 25.38, 23.17 ppm; MS-EI: m/z (%) 252 (M^+ , 60), 194 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{12}\text{H}_{14}\text{ClN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 253.0744, found: 253.0742.




2-(5-bromo-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (10): (starting material: 1.0 mmol; 0.220 g. Yield, 72%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.42-7.37 (m, 2H), 6.74 (d, 1H, $J=6.0$ Hz), 6.04 (br s, 1H), 5.25 (br s, 1H), 3.23 (s, 3H), 2.86 (d, 1H, $J=15.0$ Hz), 2.68 (d, 1H, $J=15.0$ Hz), 1.42 (s, 3H); ^{13}C NMR (CD_3OD , 75 MHz) δ 180.8, 172.6, 142.8, 135.7, 130.5, 125.2, 114.6, 109.9, 45.9, 41.7, 25.4, 23.2 ppm; MS-EI: m/z (%) 296 e 298 (M^+ , 64), 238 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{12}\text{H}_{14}\text{BrN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 297.0239, found: 297.0240.




2-(1,3-dimethyl-2-oxo-7-phenylindolin-3-yl)acetamide (11): (starting material: 4.0 mmol; 1.006 g. Yield, 85%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.43-7.35 (m, 5H), 7.28-7.25 (m, 1H), 7.13-7.06 (m, 2H), 6.52 (br s, 1H), 5.40 (br s, 1H), 2.89-2.71 (m, 5H), 1.50 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 181.6, 171.4, 139.7, 138.8, 134.2, 131.2, 129.9, 127.8, 127.7, 125.7, 122.2(2C), 121.6 (2C), 45.3, 43.7, 30.4, 23.9 ppm; MS-EI: m/z (%) 294 (M^+ , 46), 236 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 295.1446, found: 295.1450.




2-(4-chloro-3-methyl-2-oxoindolin-3-yl)acetamide (12+12' = 10:1) (major isomer): (starting material: 2.0 mmol; 0.321 g. Yield, 64%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.24-7.18 (m, 1H), 6.98 (d, 1H, $J=9.0$ Hz), 6.76 (d, 1H, $J=6.0$ Hz), 5.62 (br s, 1H), 5.12 (br s, 1H), 3.24 (s, 3H), 3.20 (d, 1H, $J=15.0$ Hz), 3.00 (d, 1H, $J=15.0$ Hz), 1.50 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 179.6, 171.0, 145.4, 129.9, 129.4, 129.0, 123.3, 106.9, 47.4, 40.9, 26.7, 21.3 ppm; MS-EI: m/z (%) 252 (M^+ , 50), 194 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{12}\text{H}_{14}\text{ClN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 253.0744, found: 253.0732.




2-(7-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (13): (starting material: 4.0 mmol; 0.369 g. Yield, 73%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.20 (d, 1H, $J=9.0$ Hz), 7.14 (d, 1H, $J=9.0$ Hz), 7.00-6.95 (m, 1H), 6.16 (br s, 1H), 5.33 (br s, 1H), 3.61 (s, 3H), 2.85 (d, 1H, $J=15.0$ Hz), 2.68 (d, 1H, $J=15.0$ Hz), 1.41 (s, 3H); ^{13}C NMR (CD_3OD , 75 MHz) δ 180.8, 171.0, 138.9, 136.0, 130.5, 123.5, 121.1, 115.8, 45.8, 43.4, 29.8, 24.1 ppm; MS-EI: m/z (%) 252 (M^+ , 52), 194 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{12}\text{H}_{14}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 253.0744, found: 253.0740.



2-(1-benzyl-3-methyl-2-oxoindolin-3-yl)acetamide (14): (starting material: 1.0 mmol; 0.279 g. Yield, 95%. dark yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.32 -7.26 (m, 6H), 7.18-7.13 (m, 1H), 7.07-7.02 (m, 1H), 6.74 (d, 1H, $J=9.0$ Hz), 6.27 (br. s, 1H), 5.34 (br s, 1H), 4.94 (s, 2H), 2.89 (d, 1H, $J=12.0$ Hz), 2.74 (d, 1H, $J=15.0$ Hz), 1.49 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.6, 171.2, 141.9, 135.7, 133.2, 128.8 (2C), 128.1, 127.6, 127.1 (2C), 122.9, 122.7, 109.4, 46.1, 43.9, 43.2, 24.1 ppm; MS-EI: m/z (%) 294 (M^+ , 18), 91 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 295.1446, found: 295.1446.




2-(3-methyl-2-oxo-1-phenylindolin-3-yl)acetamide (15): (starting material: 0.5 mmol; 0.119 g. Yield, 85%. light yellow solid) ^1H NMR (DMSO_d , 300 MHz) δ 7.45-7.21 (m, 6H), 7.02 (t, 1H, $J=6$ Hz), 6.90 (t, 1H, $J=6$ Hz), 6.52 (d, 1H, $J=9$ Hz), 2.75 (d, 1H, $J=15$ Hz), 2.62 (d, 1H, $J=15$ Hz), 1.19 (s, 3H); ^{13}C NMR (DMSO , 75 MHz) δ 179.8, 170.9, 143.9, 135.5, 133.8, 129.7 (2C), 128.0, 127.8, 127.2 (2C), 123.0, 122.4, 108.7, 45.4, 43.1, 24.9 ppm; MS-EI: m/z (%) 280 (M^+ , 72), 236 (47), 235 (67), 222 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 281.1290, found: 281.1272.




2-(1-methyl-2-oxoindolin-3-yl)-2-phenylacetamide (16:16' = 10:1) (major isomer): (starting material: 0.5 mmol; 0.076 g. Yield, 54%. white solid) ^1H NMR (CDCl_3 , 500 MHz) δ 7.31-7.25 (m, 3H), 7.23-7.20 (m, 2H), 7.13-7.05 (m, 4H), 6.23 (br s, 1H), 5.34 (br s, 1H), 4.88 (br s, 1H), 3.80 (d, 1H, $J=5$ Hz), 3.43 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 168.5, 167.3, 140.9, 138.6, 129.5, 128.9 (2C), 128.1, 127.6 (2C), 127.2, 124.1, 115.0, 55.4, 42.8, 30.1 ppm; MS-EI: m/z (%) 280 (M^+ , 2.6), 236 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 281.1290, found: 281.1271.


F. Typical procedure for carbamoylation with *N*-alkyl-formamide or *N*-aryl-formamide :⁸




To a stirring solution of *N*-arylacrylamide (1.00 mmol) and FeSO₄·7H₂O (13.9 mg, 0.05 mmol) was added the corresponding formamide (5.0 mL, in case of *N*-methylformamide and *N,N*-dimethylformamide; 2.5 mL or 2.5 g, in case of *N*-butylformamide or *N*-phenylformamide). When required, 3 mL of *t*-ButOH were added as co-solvent (see Table 1). Then, concentrated sulfuric acid 96% (56 μL, 1.00 mmol) followed by hydrogen peroxide 29% (214 μL, 2.00 mmol) were added. The mixture was heated to 65 °C and stirred for 4 h. Then, sodium bicarbonate (330.0 mg, 3.9 mmol) was added and excess of *N*-methyl-formamide was removed under reduced pressure distillation. The crude mixture was purified by flash column chromatography on silica gel using methanol/dichloromethane as eluent (10 to 20%, methanol). The product was characterized by NMR spectroscopy, mass spectrometry and high resolution mass spectrometry.




2-(1,3-dimethyl-2-oxoindolin-3-yl)-*N*-methylacetamide (3): (starting material: 5.0 mmol; 1.086 g. Yield, 94%. yellow solid) ¹H NMR (CDCl₃, 300 MHz) δ 7.30-7.24 (m, 2H), 7.07 (t, 1H, *J*=9.0 Hz), 6.86 (d, 1H, *J*=6.0 Hz), 6.39 (br s, 1H), 3.25 (s, 3H), 2.78 (d, 1H, *J*=15.0 Hz), 2.70-2.63 (m, 4H, *J*=15.0 Hz), 1.42 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 180.7, 169.6, 142.8, 133.5, 128.1, 122.8, 122.6, 108.3, 46.0, 43.7, 26.4, 26.2, 23.4 ppm; MS-EI: *m/z* (%) 232 (*M*⁺, 54), 160 (100). HRMS (ESI-TOF) *m/z*, calculated for: C₁₃H₁₇N₂O₂ [*M*+H]⁺ 233.1290, found: 233.1281.




2-(5-fluor-1,3-dimethyl-2-oxoindolin-3-yl)-*N*-methylacetamide (18): (starting material: 1.0 mmol; 0.237 g. Yield, 95%. light brown solid) ¹H NMR (CDCl₃, 300 MHz) δ 7.04-6.93 (m, 2H), 6.77 (dd, 1H, *J*=3.0 Hz, 9.0 Hz), 6.13 (br s, 1H), 3.23 (s, 3H), 2.80 (d, 1H, *J*=15.0 Hz), 2.68- 2.63 (m, 4H), 1.39 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 180.2, 169.4, 159.2 (d, C-F, *J*=240 Hz), 139.0, 135.0 (d, C-F, *J*=7.5 Hz), 114.0 (d, C-F, *J*=22.5 Hz), 110.8 (d, C-F, *J*=30 Hz), 108.6 (d, C-F, *J*=7.5 Hz), 46.4, 43.1, 26.4, 26.0, 23.7 ppm; MS-EI: *m/z* (%) 250 (*M*⁺, 68), 178 (100). HRMS (ESI-TOF) *m/z*, calculated for: C₁₃H₁₆FN₂O₂ [*M*+H]⁺ 251.1195. Found: 251.1180.




2-(1,3,5-trimethyl-2-oxoindolin-3-yl)-*N*-methylacetamide (19): (starting material: 4.0 mmol; 0.927 g. Yield, 94%. light yellow solid) ¹H NMR (CDCl₃, 300 MHz) δ 7.08-7.06 (m, 2H), 6.74 (d, 1H, *J*=9.0 Hz), 6.49 (br s, 1H), 3.21 (s, 3H), 2.72-2.66 (m, 5H), 2.33 (s, 3H), 1.40 (s, 3H); ¹³C NMR (CDCl₃, 75 MHz) δ 180.7, 169.8, 140.3, 133.6, 132.3, 128.4, 123.6, 108.0, 46.1, 43.7, 26.4, 26.2, 23.4, 21.2 ppm; MS-EI: *m/z* (%) 246 (*M*⁺, 50), 174 (100). HRMS (ESI-TOF) *m/z*, calculated for: C₁₄H₁₉N₂O₂ [*M*+H]⁺ 247.1446, found: 247.1439.




2-(5-methoxy-1,3-dimethyl-2-oxoindolin-3-yl)-N-methylacetamide (20): (starting material: 4.0 mmol; 0.997 g. Yield, 95%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 6.88 (d, 1H, $J=3.0$ Hz), 6.74-6.81 (m, 2H), 6.47 (br s, 1H), 3.79 (s, 3H), 3.22 (s, 3H), 2.70-2.78 (m, 4H), 2.64 (d, 1H, $J=15.0$ Hz), 1.41 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.4, 169.7, 156.1, 136.2, 134.9, 112.2, 110.3, 108.5, 55.8, 46.4, 43.6, 26.4, 26.1, 23.5 ppm; MS-EI: m/z (%) 262 (M^+ , 90), 190 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 263.1396, found 263.1385.¹¹




2-(5-chloro-1,3-dimethyl-2-oxoindolin-3-yl)-N-methylacetamide (21): (starting material: 2.0 mmol; 0.469 g. Yield, 88%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.22-7.26 (m, 2H), 6.77 (d, 1H, $J=6.0$ Hz), 5.96 (br s, 1H), 3.23 (s, 3H), 2.82 (d, 1H, $J=15.0$ Hz), 2.62-2.68 (m, 4H), 1.38 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.1, 169.2, 141.7, 135.2, 128.0, 127.9, 123.1, 109.2, 46.2, 43.3, 26.5, 26.2, 23.7 ppm; MS-EI: m/z (%) 266 (M^+ , 70), 194(100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{16}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 267.0900, found: 267.0896.




2-(5-bromo-1,3-dimethyl-2-oxoindolin-3-yl)-N-methylacetamide (22): (starting material: 2.0 mmol; 0.560 g. Yield, 89%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.34-7.40 (m, 2H), 6.72 (d, 1H, $J=9.0$ Hz), 5.97 (br s, 1H), 3.22 (s, 3H), 2.82 (d, 1H, $J=15.0$ Hz), 2.62-2.68 (m, 4H), 1.38 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.0, 169.2, 142.2, 135.6, 130.9, 125.8, 115.2, 109.7, 46.2, 43.3, 26.5, 26.2, 23.8 ppm; MS-EI: m/z (%) 310 (M^+ , 56), 238 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{16}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 311.0395, found: 311.0394.




2-(1,3-dimethyl-2-oxo-7-phenylindolin-3-yl)-N-methylacetamide (23): (starting material: 4.0 mmol; 1.007 g. Yield, 81%. light yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.35 (s, 5H), 7.21-7.24 (m, 1H), 7.00-7.07 (m, 2H), 6.67 (br s, 1H), 2.63-2.87 (m, 8H), 1.42 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 181.9, 180.3, 174.8, 169.9, 139.9, 138.9, 134.5, 131.0, 129.9, 127.8, 127.6, 125.5, 121.9, 121.6, 45.4, 43.7, 30.4, 26.1, 24.2 ppm; MS-EI: m/z (%) 308 (M^+ , 84), 236 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 309.1603, found: 309.1604.




2-(4-chloro-1,3-dimethyl-2-oxoindolin-3-yl)-N-methylacetamide (24:24' = 10:1) (major isomer): (starting material: 4.0 mmol; 0.779 g. Yield, 73%. light yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.14-7.21 (m, 1H), 6.93 (d, 1H, $J=6.0$ Hz), 6.74 (d, 1H, $J=9.0$ Hz), 5.79 (br s, 1H), 3.24 (s, 3H), 3.15 (d, 1H, $J=15.0$ Hz), 2.95 (d, 1H, $J=15.0$ Hz), 2.56 (d, 3H, $J=6.0$ Hz), 1.45 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 179.8, 169.5, 145.5, 129.7, 129.3, 129.2, 123.1, 106.8, 47.4, 41.5, 26.6, 26.1, 21.4 ppm; MS-EI: m/z (%) 266 (M^+ , 50), 194 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{16}\text{ClN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 267.0900, found: 267.0887.




2-(7-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)-N-methylacetamide (25): (starting material: 2.0 mmol; 0.347 g. Yield, 65%. white solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.10-7.19 (m, 2H), 6.93-6.98 (m, 1H), 6.09 (br, 1H), 3.61 (s, 3H), 2.84 (d, 1H, $J=15.0$ Hz), 2.62-2.68 (m, 4H), 1.38 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.9, 169.4, 139.0, 136.3, 130.4, 123.4, 121.0, 115.7, 45.8, 43.6, 29.8, 26.2, 24.2 ppm; MS-EI: m/z (%) 266 (M^+ , 60), 194 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{13}\text{H}_{16}\text{ClN}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 267.0900, found: 267.0897.




2-(1-Benzyl-3-Methyl-2-oxoindolin-3-yl)-N-methylacetamide (26): (starting material: 1.0 mmol; 0.251 g. Yield, 89%. dark yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.29-7.31 (m, 6H), 7.13-7.18 (m, 1H), 7.02-7.07 (m, 1H), 6.74 (d, 1H, $J=6.0$ Hz), 6.27 (br s, 1H), 4.98 (d, 1H, $J=18$ Hz), 4.92 (d, 1H, $J=15.0$ Hz), 2.84 (d, 1H, $J=15.0$ Hz), 2.72 (d, 1H, $J=12.0$ Hz), 2.66 (d, 3H, $J=3.0$ Hz), 1.48 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 180.8, 169.6, 141.8, 135.8, 133.3, 128.8 (2C), 128.1, 127.6, 127.2 (2C), 122.9, 122.8, 109.3, 46.3, 43.8, 43.7, 26.2, 24.1 ppm; MS-EI: m/z (%) 308 (M^+ , 28), 207 (52), 91 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 309.1603, found: 309.1600.



N-methyl-2-(3-methyl-2-oxo-1-phenylindolin-3-yl)acetamide (27): (starting material: 0.5 mmol; 0.100 g. Yield, 68%. light yellow solid) ^1H NMR (CHCl_3 , 300 MHz) δ 7.55-7.38 (m, 5H), 7.31-7.27 (m, 1H), 7.19 (t, 1H, $J=9$ Hz), 7.09 (t, 1H, $J=9$ Hz), 6.80 (d, 1H, $J=9$ Hz), 6.24 (br s, 1H), 2.92 (d, 1H, $J=15$ Hz), 2.76 (d, 1H, $J=15$ Hz), 2.64 (d, 3H, $J=3$ Hz), 1.51 (s, 3H); ^{13}C NMR (CHCl_3 , 75 MHz) δ 180.3, 169.6, 143.1, 134.6, 133.1, 129.6 (2C), 128.1, 128.0, 126.7 (2C), 123.1, 122.8, 109.5, 46.2, 44.0, 26.2, 24.1 ppm; MS-EI: m/z (%) 294 (M^+ , 80), 236 (39), 222 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 295.1446, found: 295.1433.




N-methyl-2-(1-methyl-2-oxoindolin-3-yl)-2-phenylacetamide (28): (starting material: 0.5 mmol; 0.077 g. Yield, 53%. yellow solid) ^1H NMR (CDCl_3 , 300 MHz) δ 7.31-7.17 (m, 5H), 7.08-7.03 (m, 4H), 6.38 (br s, 1H), 4.89 (d, 1H, $J=3$ Hz), 3.74 (d, 1H, $J=3$ Hz), 3.41 (s, 3H), 2.69 (d, 3H, $J=3$ Hz); ^{13}C NMR (CDCl_3 , 75 MHz) δ 167.6, 166.6, 141.3, 138.6, 129.5, 128.9 (2C), 128.0, 127.5 (2C), 127.1, 124.2, 114.9, 55.8, 42.7, 30.0, 26.6 ppm; MS-EI: m/z (%) 294 (M^+ , 5), 236 (100), 208 (40). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 295.1446, found: 295.1447.



2-(1,3-dimethyl-2-oxoindolin-3-yl)-N,N-dimethylacetamide (30): (starting material: 0.5 mmol; 0.0525 g. Yield, 43%. yellow liquid) ^1H NMR (CDCl_3 , 500 MHz) δ 7.34-7.09 (m, 2H), 7.00 (t, 1H, $J=10.0$ Hz), 6.90-6.85 (m, 1H), 3.27 (s, 3H), 3.03-2.94 (m, 5H), 2.76 (s, 3H), 1.36 (s, 3H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 181.0, 168.9, 143.8, 134.2, 127.6, 121.9, 121.4, 108.1, 45.7, 40.7, 37.2, 35.3, 26.4, 24.9 ppm; MS-EI: m/z (%) 246 (M^+ , 67), 160 (100). HRMS (ESI-TOF) m/z , calculated for: $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$ 247.1446, found: 247.1433.

G. Procedure for direct conversion of 8 to the corresponding methyl ester, 31:¹⁵





To the cooled methanol (20 mL, -15°C) was added the SOCl_2 (13.0 mg, 0.12 mmol), the mixture was stirred at -0°C for 30 min., then the 2-(5-methoxy-1,3-dimethyl-2-oxoindolin-3-yl)acetamide (**8**) (24.8 mg, 0.1 mmol) was added into the solution. This reaction temperature was then warmed up to 50°C for 2 days. Then a mixture of water/methanol (1/5, v/v, 5 mL) was added into the solution and then the mixture was extract by ethyl acetate three times (3 x 25 mL). The combined organic phase was dried over MgSO_4 and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel using methanol/dichloromethane as eluent (10%, methanol). The product was characterized by ^1H and ^{13}C NMR spectroscopy and mass spectrometry.



Methyl 2-(5-Methoxy-1,3-dimethyl-2-oxoindolin-3-yl)acetate (31): ^1H NMR (300 MHz, CDCl_3) δ 6.83-6.81 (m, 1H), 6.79-6.75 (m, 2H), 3.78 (s, 3H), 3.48 (s, 3H), 3.23 (s, 3H), 3.00 (d, 1H, $J = 15.0$ Hz), 2.83 (d, $J = 18.0$ Hz, 1H), 1.37 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 179.5, 170.2, 155.8, 137.1, 134.3, 111.8, 110.1, 108.3, 55.7, 51.6, 45.8, 41.2, 26.4, 24.2; MS-EI: m/z (%) 263 (M^+ , 86), 248 (39), 190 (100), 175 (16).¹⁶

H. NMR Spectra for the compounds prepared




The ^1H NMR and ^{13}C NMR of 2






The ^1H NMR and ^{13}C NMR (in methanol) of 6






The ^1H NMR and ^{13}C NMR of 7






The ^1H NMR and ^{13}C NMR of 8






The ^1H NMR and ^{13}C NMR (in Methanol) of **9**






The ^1H NMR and ^{13}C NMR of 10





The ^1H NMR and ^{13}C NMR of 11




The ^1H NMR and ^{13}C NMR of 12+12'






The ^1H NMR and ^{13}C NMR of 13








The ¹H NMR and ¹³C NMR of 14







The ¹H NMR and ¹³C NMR (in DMSO) of 15








The ¹H NMR and ¹³C NMR of 16










The ^1H NMR and ^{13}C NMR of 3






The ¹H NMR and ¹³C NMR of 18






The ^1H NMR and ^{13}C NMR of 19




The ^1H NMR and ^{13}C NMR of 20




The ^1H NMR and ^{13}C NMR of 21





The ^1H NMR and ^{13}C NMR of 22







The ¹H NMR and ¹³C NMR of 23







The ¹H NMR and ¹³C NMR of 24










The ^1H NMR and ^{13}C NMR of 25






The ^1H NMR and ^{13}C NMR of 26






The ^1H NMR and ^{13}C NMR of 27



The ^1H NMR and ^{13}C NMR of 28



The ^1H NMR and ^{13}C NMR of 30



-
- (1) Lyer, A.; Jockisch, S.; Sivaguru, J. *J. Phys. Chem. A*. **2014**, *118*, 10596.
- (2) Nishio, T.; Asai, H.; Miyazaki, T. *Helv. Chim. Acta*. **2000**, *83*, 1475.
- (3) Ortiz-de-Elguea, V.; Sotomayor, N.; Lete, E. *Adv. Synth. Catal.* **2015**, 357, 463.
- (4) Pinto, A.; Jia Dr., Y.; Neuville Dr., L.; Zhu Dr. *J. Chem. Eur. J.* **2007**, *13*, 961.
- (5) Zheng, L.; Huang, H.; Yang, C.; Xia, W. *Org. Lett.* **2015**, *17*, 1034.
- (6) Wu, T.; Mu, X.; Liu, G. *Angew. Chem. Int. Ed.* **2011**, *50*, 12578.
- (7) (a) Wei, W.; Zhou, M.; Fan, J.; Liu, W.; Song, R.; Liu, Y.; Hu, M.; Xie, P.; Li, J. *Angew. Chem. Int. Ed.* **2013**, *52*, 3638. (b) Wang, H.; Xu, C.; Zhu, W.; Liu, G.; Guo, Y. *J. Am. Soc. Mass. Spectrom.* **2012**, *23*, 2149.
- (8) Boess, E.; Karanestora, S.; Bosnidou, A.; Schweitzer-Chaput, B.; Hasenbeck, M.; Klussmann, M. *Synlett*. **2015**, *26*, 1973.
- (9) Matcha, K.; Narayan, R.; Antonchick, A. *Angew. Chem. Int. Ed.* **2013**, *52*, 7985.
- (10) Hosseini-Sarvari, M.; Sharghi, H. *Journal of Organic Chemistry*. **2006**, *71*, 6652.
- (11) Andrade, L.H.; Sousa, B.A.; Jamison, T. F. *Journal of Flow Chemistry*. **2016**, *6*, 1.
- (12) A modified version of the procedure described on Minisci, F.; Citterio, A.; Vismara, E.; Giordano, C. *Tetrahedron*. 1985, *41*, 4157.
- (13) Kobayashi, Y.; Kamisaki, H.; Takeda, H.; Yasui, Y.; Yanada, R.; Takemoto, Y. *Tetrahedron*. **2007**, *63*, 2978.
- (14) Yu, Q.S.; Luo, W.M.; Li, Y.Q.; Brossi, A. *Heterocycles*. **1993**, *36*, 1279.
- (15) Li, L.; Ren, J.; Liao, T.; Jiang, J.; Zhu, H. *Eur. J. Org. Chem.* **2007**, 1026.
- (16) Xu, X.; Tang, Y.; Li, X.; Hong, G.; Fang, M.; Du, X. *J. Org. Chem.* **2014**, *79*, 446.